Terms ending in 2030
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,198,441 | Process for the Preparation of Novel Pyridopyrazines as Mtor Kinase Inhibitors In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,093,252 | Crystalline Polymorphic Form of Glucokinase Activator In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,101,623 | A Substituted Pyrrolo[2,3-d]pyrimidine as a Protein Kinase B Inhibitor In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,198,414 | Anti-Human IL-6 Antibodies In force · High confidence | MedImmune Limited | In force | High confidence | |
| US 8,425,934 | Pharmaceutical Compositions In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,258,140 | Chemical Compounds - 643 In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 9,533,978 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases In force · Medium confidence | Sumitomo Pharma Co., Ltd. | In force | Medium confidence | |
| US 8,685,934 | Methods for Treating Extreme Insulin Resistance in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,658,641 | Fused, Spirocyclic Heteroaromatic Compounds for the Treatment of Bacterial Infections In force · High confidence | Entasis Therapeutics Inc. | In force | High confidence | |
| US 8,232,296 | Novel Salt 628 In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 11 more term ends in 2030 · Pro | |||||
10 of 21 patents shown. Soonest term end first, then patent number.
Pro members see all 21.
13 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.